Contracts are related to a $487 million biotech expansion project in Denmark and first phase of a new life sciences production facility valued at $574 million in Central U.S.
The company has secured 506 marketing approvals for its oncology products across 76 countries.
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
Marks the World Head & Neck Cancer Day at the OCTF Conference
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Subscribe To Our Newsletter & Stay Updated
